Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Acquisitions & Divestments (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $37.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 87.5% year-over-year to $37.5 million, compared with a TTM value of $127.5 million through Dec 2025, up 154.94%, and an annual FY2025 reading of $127.5 million, up 41.67% over the prior year.
  • Change in Acquisitions & Divestments was $37.5 million for Q4 2025 at Aligos Therapeutics, down from $70.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $70.0 million in Q3 2025 and bottomed at $11000.0 in Q3 2023.
  • Average Change in Acquisitions & Divestments over 5 years is $26.6 million, with a median of $22.5 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 99.97% in 2023, then skyrocketed 272627.27% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $13.0 million in 2021, then soared by 178.62% to $36.2 million in 2022, then crashed by 99.97% to $11000.0 in 2023, then soared by 181718.18% to $20.0 million in 2024, then skyrocketed by 87.5% to $37.5 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ALGS at $37.5 million in Q4 2025, $70.0 million in Q3 2025, and $20.0 million in Q1 2025.